[go: up one dir, main page]

DE69637179D1 - Angiostatinfragmente und verfahren für deren verwendung - Google Patents

Angiostatinfragmente und verfahren für deren verwendung

Info

Publication number
DE69637179D1
DE69637179D1 DE69637179T DE69637179T DE69637179D1 DE 69637179 D1 DE69637179 D1 DE 69637179D1 DE 69637179 T DE69637179 T DE 69637179T DE 69637179 T DE69637179 T DE 69637179T DE 69637179 D1 DE69637179 D1 DE 69637179D1
Authority
DE
Germany
Prior art keywords
angiostatin
fragments
proliferation inhibitor
aggregate
endothelial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69637179T
Other languages
English (en)
Other versions
DE69637179T2 (de
Inventor
M Judah Folkman
Michael S O'reilly
Yihai Cao
Jie Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/429,743 external-priority patent/US5885795A/en
Priority claimed from US08/605,598 external-priority patent/US5861372A/en
Priority claimed from US08/612,788 external-priority patent/US5837682A/en
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Application granted granted Critical
Publication of DE69637179D1 publication Critical patent/DE69637179D1/de
Publication of DE69637179T2 publication Critical patent/DE69637179T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
DE69637179T 1995-04-26 1996-04-26 Angiostatinfragmente und verfahren für deren verwendung Expired - Lifetime DE69637179T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US08/429,743 US5885795A (en) 1994-04-26 1995-04-26 Methods of expressing angiostatic protein
US429743 1995-04-26
US605598 1996-02-22
US08/605,598 US5861372A (en) 1996-02-22 1996-02-22 Aggregate angiostatin and method of use
US612788 1996-03-08
US08/612,788 US5837682A (en) 1996-03-08 1996-03-08 Angiostatin fragments and method of use
PCT/US1996/005856 WO1996035774A2 (en) 1995-04-26 1996-04-26 Angiostatin fragments and aggregate angiostatin and methods of use

Publications (2)

Publication Number Publication Date
DE69637179D1 true DE69637179D1 (de) 2007-09-06
DE69637179T2 DE69637179T2 (de) 2008-04-10

Family

ID=27411639

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69637179T Expired - Lifetime DE69637179T2 (de) 1995-04-26 1996-04-26 Angiostatinfragmente und verfahren für deren verwendung

Country Status (16)

Country Link
EP (1) EP0824546B1 (de)
JP (2) JP3787157B2 (de)
CN (1) CN1195375A (de)
AT (1) ATE368051T1 (de)
AU (1) AU709633B2 (de)
BR (1) BR9608326A (de)
CA (1) CA2219081C (de)
CZ (1) CZ334097A3 (de)
DE (1) DE69637179T2 (de)
ES (1) ES2292174T3 (de)
HU (1) HUP9800784A3 (de)
MX (1) MX9708217A (de)
NO (1) NO974943L (de)
NZ (1) NZ307044A (de)
PL (1) PL323256A1 (de)
WO (1) WO1996035774A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
US6440729B1 (en) 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
DK0869970T3 (da) * 1995-12-13 2004-07-05 Abbott Lab Endothelcelleprolifereringsinhibitor og dens anvendelse
US5801012A (en) 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin
EP1705248A1 (de) * 1997-10-01 2006-09-27 G.D. Searle LLC. Fusionsproteine mit einem angiostatin-Anteil und deren Anwendung in Antitumortherapie
AU1598599A (en) * 1997-11-20 1999-06-15 Genetix Pharmaceuticals, Inc. Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
US6797488B1 (en) 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
JP2001526031A (ja) * 1997-12-08 2001-12-18 ベス イスラエル ディーコネス メディカル センター レスチンおよびその使用方法
CA2263784A1 (en) 1998-03-23 1999-09-23 Megabios Corporation Dual-tagged proteins and their uses
DK1074264T3 (da) * 1998-04-28 2008-11-24 Toshikazu Nakamura Inhibitorer for neovaskularisering
US6770457B1 (en) 1998-05-28 2004-08-03 Korea Green Cross Corporation Process of purifying angiogenesis inhibitors
CA2335038A1 (en) 1998-06-15 1999-12-23 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
US6201104B1 (en) * 1998-12-04 2001-03-13 Entremed, Inc. Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
CA2360690A1 (en) * 1999-01-28 2000-08-03 Michael S. O'reilly Plasminogen kringle 4 region fragments and methods of use
WO2000047729A1 (en) * 1999-02-10 2000-08-17 Entremed, Inc. Deglycosylated kringle 1-5 region fragments of plasminogen and methods of use
US7157556B1 (en) 1999-02-10 2007-01-02 The Children's Medical Center Corporation Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use
PE20020376A1 (es) * 2000-09-29 2002-05-13 Abbott Lab Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
JP2006506321A (ja) * 2002-04-11 2006-02-23 チルドレンズ メディカル センター コーポレーション 血管透過性亢進を阻害する方法
CN1946430B (zh) * 2004-01-09 2012-03-21 财团法人牧岩生命工学研究所 包含人载脂蛋白(a)三环lk68或lk8基因作为有效成分用于治疗癌症的治疗剂,以及使用其治疗癌症的方法
US20110092442A1 (en) * 2004-02-24 2011-04-21 Ttc Co., Ltd Anticancer agent containing bl-angiostatin
ITMI20041962A1 (it) * 2004-10-15 2005-01-15 Istituto Naz Per La Ricerca S "peptide di angiostatina e suoi impieghio terapeutici"
CN101219219B (zh) * 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
WO2010070746A1 (ja) * 2008-12-17 2010-06-24 株式会社ティムス イヌアンジオスタチン様ポリペプチド
JP5749229B2 (ja) * 2012-07-31 2015-07-15 京セラドキュメントソリューションズ株式会社 ジェスチャー管理プログラム及び情報処理装置
ES2985007T3 (es) 2015-12-18 2024-10-31 Talengen Int Ltd Plasminógeno para su uso en el tratamiento de la nefropatía diabética
CN106890324A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病肾病的方法
WO2018107708A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种促进胰岛素受体底物-2表达的方法
EP3675889A4 (de) 2017-08-31 2021-05-12 Singapore Health Services PTE Ltd Angio-3 zur behandlung von retinalen angiogenen erkrankungen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1636594B (zh) * 1994-04-26 2012-08-29 儿童医学中心公司 血管生成抑制素和用于抑制血管生成的方法

Also Published As

Publication number Publication date
AU709633B2 (en) 1999-09-02
EP0824546A2 (de) 1998-02-25
JPH11508228A (ja) 1999-07-21
NO974943L (no) 1997-12-18
JP3787157B2 (ja) 2006-06-21
AU5579596A (en) 1996-11-29
MX9708217A (es) 1997-12-31
BR9608326A (pt) 2000-03-08
PL323256A1 (en) 1998-03-16
JP2001151691A (ja) 2001-06-05
CZ334097A3 (cs) 1998-04-15
NO974943D0 (no) 1997-10-24
HK1002457A1 (en) 1998-08-28
ATE368051T1 (de) 2007-08-15
CA2219081C (en) 2004-02-24
WO1996035774A3 (en) 1997-02-13
DE69637179T2 (de) 2008-04-10
HUP9800784A3 (en) 2000-07-28
ES2292174T3 (es) 2008-03-01
WO1996035774A2 (en) 1996-11-14
CA2219081A1 (en) 1996-11-14
EP0824546B1 (de) 2007-07-25
CN1195375A (zh) 1998-10-07
NZ307044A (en) 2002-03-01
HUP9800784A2 (hu) 1998-07-28

Similar Documents

Publication Publication Date Title
DE69637179D1 (de) Angiostatinfragmente und verfahren für deren verwendung
CA2291892A1 (en) Angiostatin fragments and method of use
DE69737397D1 (de) Verwendung von mif-antagonisten zur krebstherapie
ATE402698T1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
Shirasuna et al. Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
DE60043957D1 (de) Verfahren zur Behandlung von Entzündungen
EP1117842A4 (de) Verfahren zur selektion von behandlungsmethoden für prostatakrebs sowie behandlung von prostatakrebs
EA199800391A1 (ru) Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору
ATE411016T1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
DE60019321D1 (de) Verfahren zum screening von inhibitoren von asp2
DE69615843D1 (de) Il-8 antagonisten zur behandlung von asthma
ATE338814T1 (de) Verfahren zur kultivierung von zellen und zur vermehrung von viren
DE60044350D1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
ATE211921T1 (de) Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata
WO2000044391A3 (en) Plasminogen kringle 4 region fragments and methods of use
ATE296316T1 (de) Gegen menschliches mcm3-protein gerichtete monoklonale antikörper, verfahren zu deren herstellung und deren verwendung
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
DE69916829D1 (de) Genetisch veränderte fibroblasten und ihre verwendung
DE69425149D1 (de) Verfahren und mittel für die herstellung von bindungsproteinen für inhibitoren von plasmaproteinasen
EP1102599A4 (de) Protease hemmstoffe zur verwendung in der behandlung von psoriasis
CO4920227A1 (es) Histidina-n-bencil glicinamida sustituida con cicloalquilos .
IS1986B (is) Notkun CD137 til að stuðla að fjölgun jaðar-einkjörnunga
ATE173503T1 (de) Die verwendung des leukozyten adhäsionsmolekül-1- aus endothelzellen und antikörper dagegen in der behandlung von asthma

Legal Events

Date Code Title Description
8364 No opposition during term of opposition